- Home
- DTF vs PRLD Comparison
DTF vs PRLD Comparison
Compare DTF & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTF
- PRLD
- Stock Information
- Founded
- DTF 1991
- PRLD 2016
- Country
- DTF United States
- PRLD United States
- Employees
- DTF N/A
- PRLD N/A
- Industry
- DTF Investment Managers
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- DTF Finance
- PRLD Health Care
- Exchange
- DTF Nasdaq
- PRLD Nasdaq
- Market Cap
- DTF 79.8M
- PRLD 69.1M
- IPO Year
- DTF N/A
- PRLD 2020
- Fundamental
- Price
- DTF $11.28
- PRLD $1.76
- Analyst Decision
- DTF
- PRLD Strong Buy
- Analyst Count
- DTF 0
- PRLD 3
- Target Price
- DTF N/A
- PRLD $4.00
- AVG Volume (30 Days)
- DTF 21.1K
- PRLD 3.1M
- Earning Date
- DTF 01-01-0001
- PRLD 10-31-2025
- Dividend Yield
- DTF 3.64%
- PRLD N/A
- EPS Growth
- DTF N/A
- PRLD N/A
- EPS
- DTF 0.44
- PRLD N/A
- Revenue
- DTF N/A
- PRLD $7,000,000.00
- Revenue This Year
- DTF N/A
- PRLD N/A
- Revenue Next Year
- DTF N/A
- PRLD N/A
- P/E Ratio
- DTF $24.34
- PRLD N/A
- Revenue Growth
- DTF N/A
- PRLD N/A
- 52 Week Low
- DTF $10.29
- PRLD $0.61
- 52 Week High
- DTF $11.19
- PRLD $4.22
- Technical
- Relative Strength Index (RSI)
- DTF 39.52
- PRLD 51.40
- Support Level
- DTF $11.35
- PRLD $1.43
- Resistance Level
- DTF $11.41
- PRLD $4.19
- Average True Range (ATR)
- DTF 0.08
- PRLD 0.39
- MACD
- DTF -0.01
- PRLD 0.10
- Stochastic Oscillator
- DTF 0.00
- PRLD 19.80
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.